-+ 0.00%
-+ 0.00%
-+ 0.00%

Biomea Fusion, University of Leicester to study icovamenib plus semaglutide in obesity trial

PUBT·06/03/2026 12:01:46
Listen to the news
Biomea Fusion, University of Leicester to study icovamenib plus semaglutide in obesity trial
  • Biomea Fusion launched a University of Leicester collaboration to test menin inhibitor icovamenib with semaglutide in an obesity clinical study arm.
  • The randomized, double-blind trial will compare the combination against semaglutide alone in overweight or obese adults without type 2 diabetes.
  • The study will assess whether adding icovamenib can improve weight-loss outcomes while supporting physical function and body composition.
  • Enrollment is set to start in Q3, with the primary assessment scheduled for Week 24.
  • Late-breaking preclinical findings were scheduled for presentation at the ADA Scientific Sessions on June 7, 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biomea Fusion Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606030800PRIMZONEFULLFEED9730965) on June 03, 2026, and is solely responsible for the information contained therein.